A股異動 | 中迪投資四連板 擬收購育達健康全部股權
格隆匯11月26日丨中迪投資(000609.SZ)午後漲停,封單逾4萬手,現報6.44元,暫成交3.6億元,最新總市值19.3億元。公司上週三(20日)晚間發公告稱,為推進公司轉型發展,公司與恆泰匯金等簽訂股權轉讓框架協議,約定公司以現金方式收購育達健康100%的股權,預計本次交易構成重大資產重組。育達健康經營範圍包括醫療器械的生產、銷售及安裝等。若本次交易順利完成,將能夠有利於促進公司業務轉型發展,提升公司綜合競爭實力。公告發布後至今,中迪投資已連續四日漲停。此外據悉,中迪投資今年第三季度營收約290.6萬元,同比下滑46.38%;歸屬於上市公司股東的淨利潤約為虧損1913.9萬元,虧損同比大幅增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.